Amnolake (tamibarotene) / Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma, Rege Nephro - LARVOL DELTA

Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS. (PubMed, Blood Adv) - P3 | "The use of tamibarotene-based therapy to target RARα as a novel approach in HR-MDS pts with RARA gene overexpression is not a paradigm which can augment response rates beyond HMA monotherapy. Further explorations of alternative approaches, including those with a biomarker, to alter the natural history of this disease are warranted."

Journal • P3 data • Acute Myelogenous Leukemia • Myelodysplastic Syndrome • RARA

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials (PRNewswire) - "Rege Nephro Co., Ltd....has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc...through a mutual agreement. The acquisition was completed on February 26, 2025...Tamibarotene (RN-014) is a retinoic acid receptor agonist for which Rege Nephro is currently conducting a Phase 2 clinical trial in Japan in autosomal dominant polycystic kidney disease (ADPKD). Rege Nephro expects to initiate clinical trials in the United States, after confirming the efficacy and safety in Japan. Syros Pharmaceuticals has previously carried out a Phase 3 clinical trial of Tamibarotene for indications including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)."

Commercial • Acute Myelogenous Leukemia • Myelodysplastic Syndrome • Polycystic Kidney Disease

SELECT MDS-1: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - P3 | N=246 | Terminated | Sponsor: Syros Pharmaceuticals | N=550 ➔ 246 | Trial completion date: Feb 2029 ➔ Nov 2024 | Recruiting ➔ Terminated; As per Sponsor decision, the study was terminated.

Enrollment change • Trial completion date • Trial termination • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

Caenorhabditis Intervention Testing Program: all-trans retinoic acid-related compounds tamibarotene and bakuchiol do not extend lifespan in Caenorhabditis nematodes. (PubMed, MicroPubl Biol) - "Additionally, bakuchiol was broadly toxic at higher doses. These findings highlight the specificity of atRA's longevity effects and suggest that compounds related to atRA may not universally promote lifespan extension."

Journal

SELECT-AML-1: Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P2 | N=66 | Terminated | Sponsor: Syros Pharmaceuticals | N=95 ➔ 66 | Trial completion date: Apr 2028 ➔ Aug 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Apr 2028 ➔ Aug 2024; As per sponsor decision, the study was terminated.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Study of Tamibarotene in Patients With ADPKD (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: Rege Nephro Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease

Drug repositioning based on mutual information for the treatment of Alzheimer's disease patients. (PubMed, Med Biol Eng Comput) - "The results also highlight the diagnostic role of the 25 genes since we obtained good classification performances using a neural network model. We also suggest 12 repurposable drugs (like KU-60019, AM-630, CP55940, enflurane, ginkgolide B, linopirdine, apremilast, ibudilast, pentoxifylline, roflumilast, acitretin, and tamibarotene) interacting with 6 genes (ATM, CNR1, GLRB, KCNQ2, PDE4B, and RARA), that we linked to retrograde endocannabinoid signaling, synaptic vesicle cycle, morphine addiction, and homologous recombination."

Journal • Alzheimer's Disease • CNS Disorders • Psychiatry • ATM

Tamibarotene directly targets the NACHT domain of NLRP3 to alleviate acute myocardial infarction. (PubMed, Biochem Pharmacol) - "In a murine model of MI, Tamibarotene significantly reduced myocardial damage and improved cardiac function by inhibiting NLRP3 inflammasome activation. In summary, NLRP3 has been identified as a direct target of Tamibarotene for myocardial repair following MI, indicating that Tamibarotene could serve as a potential precursor for the development of innovative NLRP3 inhibitors."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Inflammation • Myocardial Infarction • NLRC5 • NLRP3

Abundance of Relapse-Predictive Cells Can be Estimated at Diagnosis and Is Strongly Associated with Outcome in Pediatric AML (ASH 2024) - "Patient-derived xenograft (PDX) models were treated with cytarabine (50 mg/kg/dose) or saline on days 1-4...The RARA/RXRA complex represses transcription in the absence of retinoic acid; transcription can be activated by the agonist tamibarotene (tami)...We validated the association of these cell types with chemoresistance in PDX models. We identified retinoic acid receptor agonism as a potential strategy to deplete one of these cell types."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Pediatrics • CDK6 • FLT3 • KMT2A

Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors. (PubMed, Curr Oncol) - "In the final model, the body surface area was included as a covariate for apparent total body clearance, the central compartment volume of distribution, and the peripheral compartment volume of distribution. Visual prediction checks and bootstrap analysis confirmed the validity and predictive accuracy of the final model as satisfactory."

Journal • PK/PD data • Oncology • Pediatrics • Solid Tumor

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression (Businesswire) - P3 | N=550 | SELECT MDS-1 (NCT04797780) | Sponsor: Syros Pharmaceuticals | "In the first 190 enrolled patients, the CR rate by intent-to-treat (ITT) in the tamibarotene/azacitidine treatment arm was 23.8% (n=126; 95% CI: 16.7%-32.2%) compared to a CR rate of 18.8% (n=64; 95% CI: 10.1%-30.5%) in the placebo/azacitidine control arm and was not statistically significant (p-value = 0.2084). In the safety analysis of all enrolled patients (n=245), tamibarotene in combination with azacitidine (n=160) appeared to be generally well-tolerated, with an adverse event profile that was similar to that seen in earlier Syros-sponsored studies.....SELECT-MDS-1 did not meet its primary endpoint. Company to discontinue study, review full data set, and evaluate next steps."

P3 data • Trial termination • Myelodysplastic Syndrome

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update (Businesswire) - "'We expect to announce topline results from the pivotal SELECT-MDS-1 Phase 3 trial in mid-November, and if successful, we plan to file our first New Drug Application (NDA) and to launch tamibarotene in the U.S.,'..."

P3 data: top line • Myelodysplastic Syndrome

Development of the esterase PestE for amide bond synthesis under aqueous conditions: Enzyme cascades for converting waste PET into tamibarotene. (PubMed, Angew Chem Int Ed Engl) - "Rational mutagenesis led to identification of PestE variants F33L_F289A and F33L. F33L_F289A increased conversion of N-benzylfuranamide by 1.2-fold, and F33L gave a 4-fold increase in conversion to tamibarotene."

Journal • Hematological Malignancies • Leukemia • Oncology

Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation (DGHO 2024) - "The effect of the menin inhibitor revumenib in KMT2Ar or NPM1c AML cells is significantly improved by the combination with tamibarotene. Both pronounced induction of differentiation or rapid induction of apoptosis by revumenib and tamibarotene represent promising strategies for patients with molecularly defined relapsed or refractory AML."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CDK6 • CEBPA • KMT2A • NPM1 • RARA

SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy (SOHO 2024) - P2 | "Tami-ven-aza demonstrated high CR/CRi rate and rapid onset of response in AML with RARA overexpression as a biomarker target. The combination was well tolerated with no new safety signals or increased myelosuppression compared with ven-aza. Data from a future prespecified interim analysis including at least 50% enrollment will be presented."

Clinical • Combination therapy • P2 data • Acute Myelogenous Leukemia • Oncology

Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences (Syros Press Release) - "Syros Pharmaceuticals...announced that it will present additional data from the randomized portion of the SELECT-AML-1 Phase 2 clinical trial at the Society of Hematologic Oncology (SOHO) Annual Meeting taking place September 4-7, in Houston, Texas. Additionally, Syros announced that company management will participate in the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11 in New York City."

P2 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

SELECT-AML-1: Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML (clinicaltrials.gov) - P2 | N=95 | Active, not recruiting | Sponsor: Syros Pharmaceuticals | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial (Businesswire) - P2 | N=95 | SELECT-AML-1 (NCT04905407) | Sponsor: Syros Pharmaceuticals | "Data from 51 patients enrolled in SELECT-AML-1 were reviewed on August 9, 2024. This review included a prespecified non-binding futility analysis conducted on the first 40 randomized patients after the fortieth randomized patient received approximately three months of study drug or discontinued treatment. A similar complete response (CR)/complete response with incomplete hematologic recovery (CRi) rate was observed in the triplet arm (n=20; 65%, CI: 40.8-84.6) and the doublet arm (n=20; 70%, CI: 45.7-88.1). As a result, the probability for success of the SELECT-AML-1 study to demonstrate superiority at the final analysis in 80 randomized patients was considered low, and Syros made the decision to discontinue further enrollment."

P2 data • Trial termination • Acute Myelogenous Leukemia

Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update (Syros Press Release) - "UPCOMING MILESTONES: (i) Report pivotal CR data from the SELECT-MDS-1 Phase 3 trial in newly diagnosed HR-MDS patients with RARA gene overexpression by the middle of the fourth quarter of 2024; (ii) Report clinical activity and tolerability data from a prespecified analysis of more than 40 patients from the SELECT-AML-1 Phase 2 trial in unfit AML patients with RARA overexpression at the 12th Annual Meeting of the Society of Hematologic Oncology (SOHO) meeting in September 2024."

P2 data • P3 data • Acute Myelogenous Leukemia • Myelodysplastic Syndrome

Photoinduced Cu(II)-Mediated Decarboxylative Thianthrenation of Aryl and Heteroaryl Carboxylic Acids. (PubMed, Angew Chem Int Ed Engl) - "The excellent compatibility of the method is shown by preparing a broad range of sterically and electronically varied (hetero)aryl thianthrenium salts, including derivatives of pharmaceuticals, such as ataluren, celecoxib, flavoxate, probenecid, repaglinide, and tamibarotene. Mechanistic studies are in line with a reaction occurring through a photoinduced ligand-to-metal charge transfer (LMCT) of Cu(II)-arylcarboxylates, enabling radical decarboxylative carbometallation to form arylcopper(II) intermediates that in turn react with thianthrene to form the product. Noteworthy, the susceptibility of aryl thianthrenium salts to photodegradation is overcome by a Cu(I)-driven salvage loop, which continuously intercepts the transiently formed radicals and regenerates the products."

Journal

Integrated multi-omics analysis and machine learning developed diagnostic markers and prognostic model based on Efferocytosis-associated signatures for septic cardiomyopathy. (PubMed, Clin Immunol) - "Molecular docking confirmed interactions between diagnostic genes and tamibarotene. Experimental validation supported our computational results. In conclusion, our study identifies a novel efferocytosis-related SCM subtype and diagnostic biomarkers, offering new insights for clinical diagnosis and therapy."

Journal • Machine learning • Cardiomyopathy • Cardiovascular • Infectious Disease • Inflammation • Septic Shock • CD31 • CD36 • CEBPB • MAPK3 • MAPKAPK2 • PECAM1 • SCARB1

Identification of shared disease marker genes and underlying mechanisms between rheumatoid arthritis and Crohn disease through bioinformatics analysis. (PubMed, Medicine (Baltimore)) - "Finally, tamibarotene, retinoic acid, and benzo[a]pyrene were identified as potential treatment options for patients with both RA and CD...Interestingly, the study has highlighted hsa-miR-31-5p as a potential key player in the common mechanism of both diseases, representing a new direction in research and a potential therapeutic target. These shared genes, potential mechanisms, and regulatory networks offer new opportunities for further research and may provide hope for future treatment of patients with both RA and CD."

Biomarker • Journal • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatoid Arthritis • Rheumatology • ITGB2 • MIR31

SYNERGISTIC EFFECTS OF THE RARALPHA AGONIST TAMIBAROTENE AND THE MENIN INHIBITOR REVUMENIB IN ACUTE MYELOID LEUKEMIA CELLS WITH KMT2A REARRANGEMENT OR NPM1 MUTATION (EHA 2024) - "The effect of the menin inhibitor revumenib in KMT2Ar or NPM1c AML cells is significantly improved by thecombination with tamibarotene. Both pronounced induction of differentiation or rapid induction of apoptosisby revumenib and tamibarotene represent promising strategies for patients with molecularly defined relapsedor refractory AML."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CDK6 • CEBPA • KMT2A • NPM1 • RARA

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression (Businesswire) - "Syros Pharmaceuticals....announced that it will host a webcast event with medical experts to discuss the unmet need in higher-risk myelodysplastic syndrome (HR-MDS) and the opportunity for tamibarotene to transform the care of newly diagnosed patients with RARA gene overexpression. The event will take place on Tuesday, June 25, 2024, from 11:00 a.m. – 12:30 p.m. ET...Syros expects to report pivotal complete response data from the SELECT-MDS-1 trial by the middle of the fourth quarter of 2024 and will report clinical activity and tolerability data from a prespecified analysis of over 40 patients from the SELECT-AML-1 trial in the third quarter of 2024...The speakers will provide a disease overview of HR-MDS, including current therapies and approach to patient management, evaluation of patient outcomes in HR-MDS trials, and the emerging treatment landscape and ongoing areas of unmet need....discuss previously presented clinical data supporting the development of tamibarotene..."

Clinical • P2 data • P3 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update (Syros Press Release) - "In March, the Phase 3 SELECT-MDS-1 clinical trial of tamibarotene passed a pre-specified interim futility analysis based on the CR rate, which was conducted by an Independent Data Monitoring Committee (IDMC). There were no concerning safety signals noted in the analysis and the IDMC recommended SELECT-MDS-1 continue without modification. Syros remains blinded to the data."

DSMB • Trial status • Hematological Malignancies • Myelodysplastic Syndrome • Oncology